Personalis (PSNL) Stock Price

Personalis Price

NASDAQ·CLOSED
13.51USD-0.01 (-0.07 %)
Market closed

Over the last 8 years Personalis grew revenue by 30.8% annually, reaching 69.44 M USD. For Personalis, the net margin of -117.0% is down versus -76.5% a few years ago. The consensus 12-month price target for Personalis is 11.22 USD, about 17.0% below where the stock trades today. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus. Personalis's share price has gained 206.7% over the last twelve months. The stock trades about 200% above its 52-week low.

Personalis stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Personalis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Personalis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Personalis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Personalis Stock Price History
DatePersonalis Price
8/5/202613.51 USD
8/4/202613.52 USD
8/3/202613.20 USD
7/31/202612.66 USD
7/30/202612.28 USD
7/29/202611.68 USD
7/27/202611.77 USD
7/23/202612.22 USD
7/22/202612.47 USD
7/21/202613.44 USD
7/20/202613.34 USD
7/17/202615.39 USD
7/16/202615.58 USD
7/15/202615.79 USD
7/14/202615.03 USD
7/13/202615.45 USD
7/10/202614.07 USD
7/9/202614.65 USD
7/8/202613.46 USD
7/7/202613.98 USD
7/6/202613.50 USD
7/2/202613.62 USD
7/1/202613.79 USD
6/30/202613.40 USD
6/29/202613.41 USD
6/26/202613.02 USD
6/25/202612.59 USD
6/24/202611.36 USD
6/23/202610.06 USD
6/22/202610.02 USD
6/18/20269.98 USD
6/17/202610.45 USD
6/16/202610.35 USD
6/15/202610.23 USD
6/12/20269.50 USD
6/11/20269.45 USD
6/10/202610.07 USD
6/9/20269.75 USD
6/8/202610.04 USD
6/5/202611.21 USD
6/4/202612.26 USD
6/3/202610.90 USD
6/2/202610.96 USD
6/1/202611.16 USD
5/29/202611.77 USD
5/28/202610.43 USD
5/27/20269.16 USD
5/26/20269.07 USD
5/22/20268.42 USD
5/21/20268.34 USD
5/20/20267.64 USD
5/19/20267.04 USD
5/18/20266.72 USD
5/15/20266.36 USD
5/14/20266.71 USD
5/13/20266.39 USD
5/12/20266.04 USD
5/11/20265.78 USD
5/8/20265.98 USD
5/7/20265.99 USD
5/6/20266.07 USD
5/5/20265.56 USD
5/4/20265.90 USD
5/1/20265.78 USD
4/30/20265.52 USD
4/29/20265.04 USD
4/28/20265.50 USD
4/27/20265.96 USD
4/24/20266.10 USD
4/23/20265.96 USD
4/22/20266.31 USD
4/21/20266.24 USD
4/20/20266.34 USD
4/17/20266.73 USD
4/16/20266.66 USD
4/15/20266.63 USD
4/14/20266.68 USD
4/13/20266.31 USD
4/10/20266.02 USD
4/9/20266.09 USD
4/8/20266.33 USD
4/7/20266.17 USD
4/6/20266.58 USD
4/2/20266.58 USD
4/1/20266.56 USD
3/31/20266.37 USD
3/30/20266.24 USD
3/27/20266.34 USD
3/26/20267.32 USD
3/25/20267.70 USD
3/24/20267.78 USD
3/23/20267.61 USD
3/20/20267.26 USD
3/19/20267.19 USD
3/18/20266.96 USD
3/17/20267.12 USD
3/16/20266.79 USD
3/13/20266.72 USD
3/12/20266.59 USD
3/11/20267.95 USD
3/10/20268.31 USD
3/9/20268.16 USD
3/6/20267.84 USD
3/5/20268.56 USD
3/4/20268.93 USD
3/3/20268.67 USD
3/2/20269.06 USD
2/27/20269.06 USD
2/26/20269.03 USD
2/25/20268.31 USD
2/24/20268.29 USD
2/23/20268.29 USD
2/20/20268.28 USD
2/19/20268.91 USD
2/18/20269.00 USD
2/17/20268.57 USD
2/13/20268.21 USD
2/12/20268.39 USD
2/11/20268.90 USD
2/10/20268.62 USD
2/9/20267.83 USD
2/6/20268.06 USD
2/5/20267.42 USD
2/4/20268.31 USD
2/3/20269.20 USD
2/2/20269.35 USD
1/30/20269.37 USD
1/29/20269.97 USD
1/28/20269.99 USD
1/27/202610.32 USD
1/26/202610.36 USD
1/23/202610.17 USD
1/22/202611.25 USD
1/21/20269.65 USD
1/20/20269.39 USD
1/16/20269.89 USD
1/15/20269.61 USD
1/14/20269.30 USD
1/13/20268.78 USD
1/12/20268.57 USD
1/9/20268.10 USD
1/8/20268.38 USD
1/7/20269.35 USD
1/6/20269.15 USD
1/5/20268.02 USD
1/2/20267.85 USD
12/31/20257.96 USD
12/30/20257.97 USD
12/29/20257.93 USD
12/26/20258.14 USD
12/24/20258.41 USD
12/23/20258.42 USD
12/22/20258.72 USD
12/19/20258.55 USD
12/18/20257.93 USD
12/17/20257.74 USD
12/16/20257.98 USD
12/15/20258.48 USD
12/12/20258.77 USD
12/11/20259.28 USD
12/10/20259.27 USD
12/9/20259.26 USD
12/8/20259.82 USD
12/5/20259.56 USD
12/4/202510.48 USD
12/3/202510.17 USD
12/2/202510.10 USD
12/1/20259.68 USD
11/28/202510.73 USD
11/26/202510.72 USD
11/25/202511.21 USD
11/24/20259.99 USD
11/21/20259.73 USD
11/20/20258.28 USD
11/19/20258.24 USD
11/18/20257.62 USD
11/17/20257.48 USD
11/14/20257.51 USD
11/13/20257.60 USD
11/12/20258.01 USD
11/11/20258.44 USD
11/10/20258.63 USD
11/7/20256.93 USD
11/6/20257.19 USD
11/5/20257.66 USD
11/4/20258.73 USD
11/3/20259.00 USD
10/31/20259.64 USD
10/30/20259.51 USD
10/29/20259.55 USD
10/28/20259.75 USD
10/27/20259.68 USD
10/24/20259.68 USD
10/23/20259.45 USD
10/22/20258.93 USD
10/21/20259.57 USD
10/20/202510.12 USD
10/17/20259.13 USD
10/16/202510.28 USD
10/15/20258.53 USD
10/14/20258.22 USD
10/13/20258.23 USD
10/10/20258.12 USD
10/9/20258.61 USD
10/8/20258.68 USD
10/7/20257.57 USD
10/6/20257.20 USD
10/3/20257.34 USD
10/2/20256.77 USD
10/1/20256.91 USD
9/30/20256.52 USD
9/29/20256.35 USD
9/26/20256.04 USD
9/25/20255.98 USD
9/24/20256.06 USD
9/23/20256.11 USD
9/22/20256.16 USD
9/19/20256.10 USD
9/18/20255.82 USD
9/17/20255.73 USD
9/16/20255.87 USD
9/15/20255.93 USD
9/12/20255.85 USD
9/11/20256.10 USD
9/10/20255.39 USD
9/9/20255.39 USD
9/8/20255.32 USD
9/5/20255.24 USD
9/4/20255.09 USD
9/3/20254.85 USD
9/2/20254.81 USD
8/29/20254.89 USD
8/28/20254.78 USD
8/27/20254.78 USD
8/26/20254.88 USD
8/25/20254.70 USD
8/22/20254.83 USD
8/21/20254.66 USD
8/20/20254.64 USD
8/19/20254.53 USD
8/18/20254.85 USD
8/15/20254.60 USD
8/14/20254.66 USD
8/13/20254.83 USD
8/12/20254.57 USD
8/11/20254.50 USD
8/8/20254.51 USD
8/7/20254.55 USD
8/6/20254.41 USD
Access this data via the Eulerpool API
Get Free API Key

Personalis Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
73.37 M USD
-109.94 M USD
-108.30 M USD
Jan 1, 2024
84.59 M USD
-68.27 M USD
-81.28 M USD
Jan 1, 2025
69.44 M USD
-88.06 M USD
-81.27 M USD
Jan 1, 2026 (e)
78.89 M USD
-42.93 M USD
-91.32 M USD
Jan 1, 2027 (e)
110.32 M USD
-60.03 M USD
-78.59 M USD
Jan 1, 2028 (e)
151.70 M USD
-82.55 M USD
-60.09 M USD
Jan 1, 2029 (e)
184.10 M USD
-100.18 M USD
-51.50 M USD
Jan 1, 2030 (e)
227.40 M USD
-123.74 M USD
-41.74 M USD

Personalis Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 8:21 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e
9.0037.0065.0078.0085.0065.0073.0084.0069.0078.00110.00151.00184.00227.00
–311.1175.6820.008.97-23.5312.3115.07-17.8613.0441.0337.2721.8523.37
-22.2229.7333.8525.6436.4720.0024.6630.95-76.81-76.81-76.81-76.81-76.81-76.81
-2.0011.0022.0020.0031.0013.0018.0026.00-53.00-59.91-84.49-115.99-141.33-174.36
-22.00-17.00-22.00-42.00-65.00-115.00-109.00-68.00-88.00-42.00-60.00-82.00-100.00-123.00
-244.44-45.95-33.85-53.85-76.47-176.92-149.32-80.95-127.54-53.85-54.55-54.30-54.35-54.19
-23.00-19.00-25.00-41.00-65.00-113.00-108.00-81.00-81.00-91.00-78.00-60.00-51.00-41.00
–-17.3931.5864.0058.5473.85-4.42-25.00–12.35-14.29-23.08-15.00-19.61
3.0021.7531.2134.9244.8146.2649.4372.8892.2892.2892.2892.2892.2892.28
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Personalis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Personalis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Personalis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Personalis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Personalis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Personalis stock margins

The Personalis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Personalis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Personalis.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
37.11 %
-76.61 %
-76.46 %
Jan 1, 2022
20.59 %
-178.16 %
-174.74 %
Jan 1, 2023
24.82 %
-149.84 %
-147.60 %
Jan 1, 2024
31.71 %
-80.70 %
-96.09 %
Jan 1, 2025
-77.58 %
-126.80 %
-117.03 %
Jan 1, 2026 (e)
-77.58 %
-54.42 %
-115.76 %
Jan 1, 2027 (e)
-77.58 %
-54.42 %
-71.24 %
Jan 1, 2028 (e)
-77.58 %
-54.42 %
-39.61 %

Personalis Stock Revenue, EBIT, Earnings per Share

The Personalis earnings per share therefore indicates how much revenue Personalis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.90 USD
-1.46 USD
-1.46 USD
Jan 1, 2022
1.40 USD
-2.50 USD
-2.45 USD
Jan 1, 2023
1.48 USD
-2.22 USD
-2.19 USD
Jan 1, 2024
1.16 USD
-0.94 USD
-1.12 USD
Jan 1, 2025
0.75 USD
-0.95 USD
-0.88 USD
Jan 1, 2026 (e)
0.89 USD
-0.47 USD
-1.03 USD
Jan 1, 2027 (e)
1.24 USD
-0.65 USD
-0.89 USD
Jan 1, 2028 (e)
1.71 USD
-0.89 USD
-0.68 USD

Personalis business model & stock analysis

Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients.

Personalis SWOT Analysis

Strengths

Personalis Inc, being a leading genomic data company, possesses several strengths that give it a competitive edge in the market. These strengths include:

  • Cutting-edge technology and expertise in genomics
  • Strong partnerships with top pharmaceutical and biotech companies
  • Wide range of genomic analysis services
  • Strong track record of delivering accurate and reliable results
  • Ability to handle large-scale genomic data and provide meaningful insights

Weaknesses

Despite its strengths, Personalis Inc also faces certain weaknesses that need to be addressed to maintain its competitive position:

  • Dependence on collaborations for research and development
  • Relatively high cost of its genomic analysis services compared to competitors
  • Limited brand awareness outside the genomics industry
  • Potential for data privacy and security concerns
  • Lack of diversification in service offerings

Opportunities

Personalis Inc has several opportunities that it can capitalize on to further grow and expand its business:

  • Increasing demand for genomic data in precision medicine
  • Growing interest in personalized healthcare and diagnostics
  • Emerging markets for genomic analysis services
  • Potential for strategic partnerships with healthcare providers
  • Expanding use of genomics in agriculture and veterinary sciences

Threats

Personalis Inc should also be aware of potential threats that could impact its business and take necessary precautions:

  • Intense competition from established genomics companies
  • Regulatory challenges and evolving industry standards
  • Economic downturns affecting healthcare spending
  • Rapid technological advancements making current offerings obsolete
  • Potential legal and ethical concerns surrounding genomic data usage

Personalis Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Personalis Employees
Details
Date
Personalis Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Personalis Segments

Personalis Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Personalis historical P/E ratio, EBIT multiple, and P/S ratio

Personalis annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Personalis shares outstanding

The number of shares of Personalis was 92.28 M in 2025. This indicates how many shares Personalis is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
44.81 M Stocks
Jan 1, 2022
46.26 M Stocks
Jan 1, 2023
49.43 M Stocks
Jan 1, 2024
72.88 M Stocks
Jan 1, 2025
92.28 M Stocks
Jan 1, 2026 (e)
92.28 M Stocks
Jan 1, 2027 (e)
92.28 M Stocks
Jan 1, 2028 (e)
92.28 M Stocks

Current Personalis forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
84.62 % (11)
Hold
15.38 % (2)
Sell
0.00 % (0)
12M Price Target
11.22
Last Price
13.51
Currency
USD
12M Return Potential
-16.95 %
LTM Return
0 %

Personalis Analyst Rating Actions

DateFirmActionRatingReliability
7/20/2026
Needham
Needham
DowngradeBuyHold70
7/20/2026
Lake Street
Lake Street
DowngradeBuyHold–
7/20/2026
BTIG
BTIG
MaintainedBuy–
7/17/2026
Needham
Needham
MaintainedBuy70
7/9/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
5/12/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
5/11/2026
BTIG
BTIG
MaintainedBuy–
3/5/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
2/27/2026
Needham
Needham
MaintainedBuy70
2/11/2026
BTIG
BTIG
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Personalis Earnings Calls

2025

Personalis Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/11/2026-0.27USD-17.12 MUSD-2026 Q2
5/6/2026-0.28USD-14.77 MUSD-2026 Q1
2/26/2026-0.30USD-17.73 MUSD-2025 Q4
5/1/2024-0.51USD-19.31 MUSD-2024 Q1
2/21/2024-0.51USD-20.01 MUSD-2023 Q4
8/1/2023-0.62USD-24.50 MUSD-2023 Q2
5/2/2023-0.63USD-20.91 MUSD-2023 Q1
2/22/2023-0.65USD-15.56 MUSD-2022 Q4
11/2/2022-0.66USD-13.84 MUSD-2022 Q3
8/3/2022-0.64USD-15.73 MUSD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the Personalis stock

45/100
48
Environment
49
Social
37
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Personalis shareholder structure

% Name
15.81638%
Merck & Co Inc
Merck & Co Inc
14.32297%
Tempus AI Inc
Tempus AI Inc
9.19002%
Lightspeed Venture Partners
Lightspeed Venture Partners
8.00442%
ARK Investment Management LLC
ARK Investment Management LLC
4.27486%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
3.53273%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
...

Personalis Beneficial Ownership Filings (SEC 13D/G)

Free Float
60.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
24.62%
RAVI MHATRE
RAVI MHATRE
SEC ↗
19.06%
PETER Y. NIEH
PETER Y. NIEH
SEC ↗
19.06%
BARRY EGGERS
BARRY EGGERS
SEC ↗
15.80%
Tempus Labs, Inc.
Tempus Labs, Inc.
SEC ↗
12.50%
Tempus AI, Inc.
Tempus AI, Inc.
SEC ↗
11.71%
JEREMY LIEW
JEREMY LIEW
SEC ↗
11.60%
Abingworth LLP
Abingworth LLP
SEC ↗
11.60%
Abingworth Bioventures V, LP
Abingworth Bioventures V, LP
SEC ↗
9.50%
JPMORGAN CHASE & CO.13-2624428
JPMORGAN CHASE & CO.13-2624428
SEC ↗
8.14%
ARK Investment Management LLC
ARK Investment Management LLC
SEC ↗

Personalis Executives and Management Board

10 members · avg. age 65 · 30 % women

CH

Mr. Christopher Hall (56)

President, Chief Executive Officer, Director · since 2022

1.54 M USD

Management

AT

Mr. Aaron Tachibana (64)

Chief Financial Officer, Chief Operating Officer

1.01 M USD
RC

Dr. Richard Chen (54)

Executive Vice President - Research and Development, Chief Medical Officer

989,394.00 USD
SM

Mr. Stephen Moore (53)

Senior Vice President, Chief Legal Officer, and Corporate Secretary

674,279.00 USD

Board of Directors

KE

Ms. Karin Eastham (75)

Independent Chairman of the Board

165,810.00 USD
AB

Mr. A. Blaine Bowman (78)

Independent Director

110,810.00 USD
OB

Ms. Olivia Bloom (56)

Independent Director

110,487.00 USD
WM

Mr. Woodrow Myers (71)

Independent Director

98,310.00 USD
LS

Ms. Lonnie Shoff (66)

Independent Director

93,310.00 USD
KW

Dr. Kenneth Widder (72)

Independent Director

90,810.00 USD

Frequently asked questions about Personalis

The business model of Personalis Inc is focused on genomic data and precision medicine. The company offers advanced genomic sequencing and analysis services to researchers, pharmaceutical companies, and healthcare providers. Personalis Inc leverages its expertise in genomics to analyze and interpret genetic information, helping customers gain insights into complex diseases and develop targeted therapies. With a comprehensive suite of proprietary technologies and a vast genomic database, Personalis Inc aims to revolutionize healthcare by delivering personalized solutions for better patient outcomes.

Personalis Inc is primarily active in the biotechnology industry.

The main competitors of Personalis Inc in the market include companies like Illumina, Inc., Foundation Medicine, Inc., and Exact Sciences Corporation.

Personalis Inc. is a renowned genomic sequencing and data analysis company based in California. Founded in 2010, Personalis specializes in advanced technologies that enable the study of genomics at an unprecedented scale. The company combines extensive reference data with state-of-the-art analytics to provide accurate and comprehensive genomic information. Personalis has built strong capabilities in cancer genomics, aiding in the development of personalized cancer therapies. With its proprietary biotechnology platforms, Personalis offers highly accurate sequencing capabilities as well as innovative systems for analyzing genomic data. Continuously expanding its expertise and collaborations, Personalis Inc. remains at the forefront of genomic research and precision medicine.

Personalis Inc has achieved several significant milestones throughout its journey. One noteworthy achievement is the successful completion of its initial public offering (IPO) in June 2019, which marked a pivotal moment for the company. Additionally, Personalis Inc has made remarkable strides in the field of advanced genomics, providing comprehensive and accurate genomic sequencing and interpretation solutions. The company's commitment to innovation has led to various collaborations with renowned pharmaceutical and biotechnology companies, further strengthening its market position and expanding its reach. Through its consistent dedication, Personalis Inc has established itself as a leading player in the genomics industry.

Personalis Inc is primarily present in the United States and operates globally.

Personalis Inc represents a strong commitment to leveraging genomics to advance the field of precision medicine. The company focuses on providing comprehensive, accurate, and reliable genomic data to empower healthcare professionals and researchers. Personalis Inc values innovation and excellence in developing cutting-edge technologies to deliver personalized insights into an individual's genetic makeup. With an emphasis on collaboration and integrity, Personalis Inc aims to drive breakthroughs in disease research, drug development, and patient care. By harnessing the power of genomics, Personalis Inc is dedicated to improving health outcomes and transforming the future of precision medicine.

Analysts currently set an average price target of 11.22 USD for the Personalis stock (median: 11.22 USD), implying -17.0 % versus the latest price. The consensus is based on 13 analyst ratings.

Personalis Analyst Price Targets 2026

13 analysts currently rate the Personalis stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Personalis to generate revenue of 78.89 M USD and earnings per share of -0.99 USD.

Personalis Analyst Price Targets 2026

Converted at the current exchange rate, the Personalis share trades at 11.70 EUR (13.51 USD).

The Personalis share (PSNL) is listed on 4 stock exchanges, including: NASDAQ (PSNL), Frankfurt (04X.F), München (04X.MU), Düsseldorf (04X.DU).

Personalis Inc. is a company from the USA specializing in the development of personalized diagnostic and treatment solutions. The company operates in different sectors, each of which contributes uniquely to strengthening the company's life cycle. The first sector of Personalis is cancer genomics. The company has developed a platform that allows for the analysis of the genomics of cancer cells. The process involves sequencing DNA and RNA to obtain accurate information about the tumor type and its variations. With this information, Personalis develops strategies for the treatment of cancer patients and provides personalized treatment plans to its customers. Another important aspect of Personalis is genomics in immunology. Personalis utilizes its expertise to modulate the immune system of patients. The company has developed a technology that captures information about genetic variations in the immune system and uses this information to create personalized immunotherapies. This approach opens new avenues for developing treatment solutions for autoimmune diseases and other immune disorders. Personalis also has a services department that offers personalized diagnostic and treatment solutions to clinical and pharmaceutical customers. The company provides a wide range of services based on genomics, immunology, and other areas of personalized medicine. Personalis also serves the research sector through its services, equipping research laboratories in the biotechnology industry with the latest technologies to accelerate the progress of personalized medicine. The products offered by Personalis include the Cancer Genome Atlas (TCGA), a comprehensive dataset of DNA sequencing data provided to research laboratories to better understand cancer genomics and the mechanisms underlying cancer development. Personalis also offers the IMPACT test, a diagnostic platform that allows for the identification of genetic anomalies in cancer cells through sequencing. Personalis' business strategy focuses on the development of personalized diagnostic and treatment solutions, taking future advancements in medicine and biotechnology into account. Personalis aims to provide patients with the opportunity to receive the best possible treatment for their illness by leveraging the genetic information of their disease. In summary, Personalis Inc. offers innovative solutions for diagnostics and treatment through personalized medicine. With its expertise in genomics and immunology, the company covers various business fields. Personalis relies on the use of cutting-edge technologies to offer personalized solutions tailored to the specific needs of its customers. The company clearly positions itself as a leader in personalized medicine.

The expected revenue of Personalis is 78.89 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Personalis is -91.32 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Personalis is currently -13.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Personalis stock.

The price-to-sales ratio (P/S) of Personalis is currently 15.80. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Personalis stock.

The Eulerpool Quality Score for Personalis is 2/10.

The ISIN of Personalis is US71535D1063. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Personalis is A2PLTK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Personalis is PSNL. The ticker symbol is used to trade Personalis shares on the stock exchange.

Personalis paid dividends every year for the past 0 years.

Personalis is assigned to the 'Health' sector.

The dividends of Personalis are distributed in USD.

All fundamentals and in-depth analysis of Personalis

Our stock analysis for Personalis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Personalis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Personalis Stock
Personalis Revenue→
Personalis Stock
Personalis Net Income→
Personalis Stock
Personalis P/E→
Personalis Stock
Personalis P/S→
Personalis Stock
Personalis EBIT→
Personalis Stock
Personalis Dividend→
Personalis Stock
Personalis Directors Dealings→
Personalis Stock
Personalis Stocks→
Personalis Stock
Personalis Market capitalization→
Personalis Stock
Personalis Debt→
Personalis Stock
Personalis Liabilities→
Personalis Stock
Personalis Equity→
Personalis Stock
Personalis AAQS→
Personalis Stock
Personalis Employees→
Personalis Stock
Personalis ROE→
Personalis Stock
Personalis ROA→
Personalis Stock
Personalis ROCE→
Personalis Stock
Personalis News→
Personalis Stock
Personalis Analyst Price Targets→

Health Stocks

Perspective TherapeuticsPerseus ProteomicsPet Pharm Biotech CoPerrigo CompanyPetros PharmaceuticalsPerpetua Medical AB (publ)PetVivo HoldingsPerfect Medical Industry CoPfizerPercheron TherapeuticsPfizerPeptronAll Stocks A–Z →